Mepolizumab (6) – Nucala®

Name: Frühe Nutzenbewertungen nach § 35a SGB V
Creator: Gemeinsamer Bundesausschuss

COPD

Start date	15.03.2026
Resolution	03.09.2026 – active procedure
INN	Mepolizumab
Brand name	Nucala®
Pharm. company	GlaxoSmithKline GmbH & Co. KG
G-BA Procedure ID	D-1294
Therapeutic area	Respiratory system diseases
Reason for procedure	New therapeutic indication

active procedures repealed resolutions


15.03.2026	03.09.2026	Mepolizumab (6)	Nucala®	GlaxoSmithKline GmbH & Co. KG	Respiratory system diseases	COPD	n.d.	active procedure
01.12.2021	19.05.2022	Mepolizumab (4)	Nucala®	GlaxoSmithKline GmbH & Co. KG	Musculoskeletal system diseases	Eosinophilic granulomatosis with polyangiitis	80–1,130	100% additional benefit not proven
01.12.2021	19.05.2022	Mepolizumab (3)	Nucala®	GlaxoSmithKline GmbH & Co. KG	Respiratory system diseases	Chronic rhinosinusitis with nasal polyps	10,500–12,600	100% additional benefit not proven
01.12.2021	19.05.2022	Mepolizumab (5)	Nucala®	GlaxoSmithKline GmbH & Co. KG	Hematopoietic diseases	Hypereosinophilic syndrome	100–400	100% Hint for considerable additional benefit
01.10.2018	22.03.2019	Mepolizumab (2)	Nucala®	GlaxoSmithKline GmbH & Co. KG	Respiratory system diseases	Bronchial asthma, ≥ 6 to < 18 years	2,200–3,500	100% additional benefit not proven
01.02.2016	21.07.2016	Mepolizumab (1)	Nucala®	GlaxoSmithKline GmbH & Co. KG	Respiratory system diseases	Bronchial asthma	16,000–100,000	50% Hint for minor additional benefit

<< List of all resolutions